We have characterized the pharmacological profile of the nonpeptide tachykinin NK 2 receptor antagonist ibodutant (MEN15596) through radioligand binding and contractility assays in the human colon smooth muscle. The antagonist affinity of ibodutant was evaluated through concentrationdependent inhibition curves at the [ 125 I]NKA specific binding by using membranes prepared from human colon smooth muscle. In this assay the affinity of ibodutant (pK i 9.9) was compared to that of other two selective NK 2 receptor antagonists, nepadutant (pK i 8.4) and saredutant (pK i 9.2). The antagonist potency of ibodutant was evaluated towards the [bAla 8 ]NKA(4-10)-mediated contractions of human colon smooth muscle strips. In this assay ibodutant (3, 10, 30 and 100 nM) induced a concentration-dependent rightward shift of the [bAla 8 ]NKA(4-10) concentration-response curves without depressing the maximal contractile effect. The analysis of the curves yielded a Schild-plot linear regression with a slope not different from unity (1.02), thus indicating a surmountable antagonist behavior. The calculated apparent antagonist potency as pK B value was 9.1. No sex related differences were observed in NK 2 receptor pharmacology for [bAla 8 ]NKA(4-10) or ibodutant in colonic strips obtained from male or female patients. Reversibility experiments of tachykinin NK 2 receptor blockade indicated that the inhibition of the agonist-induced contractions in preparations pre-exposed to ibodutant, and afterwards subjected to repeated washing cycles remained almost constant showing no sign of recovery during the 3 h observation period. Overall, the present study indicates ibodutant as a potent tachykinin NK 2 receptor antagonist in the human colon tissue, also endowed with a persistent duration of action.
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Introduction
Tachykinin receptors, namely NK 1 , NK 2 and NK 3 , are seven transmembrane class-A (rhodopsin-like) G-protein coupled receptors, widely expressed in the central and peripheral mammal tissues (Shimizu et al., 2008) . In the mammalian intestine, tachykinins play a role as excitatory transmitters that mediate the ascending excitatory reflex and atropine-resistant peristalsis (Barthó and Holzer, 1985; Costa et al., 1985; Maggi et al. 1994) either directly on muscle cells or indirectly by activating intramural neurons (Barthó and Holzer, 1985; Holzer and Holzer-Petsche, 1997a, b) . In human intestine tachykinin-like immunoreactivity originates primarily from intrinsic neurons but also from the peripheral endings of capsaicin-sensitive afferent neurons (Holzer and Holzer-Petsche, 1997a ). In the human colon, the tachykinin receptors mediating smooth muscle contraction belong, for the most part, to the NK 2 type (Maggi et al., 1993 ) although radioligand binding studies (Warner et al., 1999) have revealed the presence of a small population of NK 1 receptors, whose functional role remains to be elucidated.
In this view, tachykinin NK 2 receptor antagonists are regarded as possible candidates for counteracting altered smooth muscle motility and visceral hypersensitivity present in pathological conditions characterized by an inflammatory state and impaired motility such as irritable bowel syndrome (IBS) (Lecci et al., 2004 for review), and represent potential innovative therapeutic drugs Quartara et al., 2009) .
We recently developed a new potent tachykinin NK 2 receptorselective nonpeptide antagonist, ibodutant (previously named MEN15596) that is presently undergoing Phase-IIb clinical trial for treatment of diarrhea-predominant IBS. The pharmacological outlines of ibodutant have indicated its high affinity and selectivity for the human tachykinin NK 2 receptor over the NK 1 and NK 3 and subnanomolar antagonist potency in human, guinea-pig, and minipig in vitro bioassays (Cialdai et al., 2006) . Moreover, ibodutant displays a long duration of action both in vivo and in vitro, due to its bioavailability, metabolic resistance, and long residence time on the tachykinin NK 2 receptor (Cialdai et al., 2006; Meini et al., 2009) .
Smooth muscle preparations of the human colon have been previously used to characterize both the potency and affinity of different tachykinin NK 2 receptor antagonists (Giuliani et al., 1991; Advenier et al., 1992; Warner et al., 1999; Patacchini et al., 2000) . Therefore, the present investigation was undertaken to characterize the pharmacological properties of ibodutant at the tachykinin NK 2 receptor in the circular muscle of the human colon. Radioligand binding experiments using iodinated neurokinin-A (NKA) and smooth muscle membranes were performed to assess ibodutant affinity in comparison to that of other tachykinin NK 2 receptor antagonists (nepadutant and saredutant, formerly known as MEN11420 and SR48968; Catalioto et al., 1998; Emonds-Alt et al., 1993) . Smooth muscle contractility experiments were performed to evaluate the ibodutant antagonist potency and the reversibility of receptor blockade towards the responses produced by the tachykinin NK 2 receptor selective agonist [bAla 8 ]NKA(4-10). Moreover, since some sex-related variations in NK 2 receptor pharmacology in human colon have been described (Burcher et al., 2008) we assessed whether the response to NK 2 receptor agonist and antagonist differs, at some extent, in colonic strips from male and female patients.
Materials and methods

Patients and specimens
All the procedures used in the present study were approved by the Ethics Committee of the Medical Faculty of Florence University. Written informed consent was obtained from all patients.
Segments of human colon, approximately 10 cm in length, were taken from grossly normal margins of surgical resections from 16 patients (7 males and 9 females, age range 47-84 years) undergoing partial colectomy for adenocarcinoma. Most segments were taken from the descending colon (9) and some from sigmoid (3), ascending (2) and transverse (2) colon.
Immediately after resection, colonic segments were placed in ice-cold Ringer-lactate solution and quickly transported to the laboratory. No patient received radio or chemotherapy before intervention. All specimens appeared macroscopically normal, with no signs of tumor or inflammation.
The tissue was transferred into fresh oxygenated (95% O 2 and 5% CO 2 ) ice-cold Krebs solution of the following composition (mmol/l): NaCl 119; NaHCO 3 25; KH 2 PO 4 1.2; MgSO 4 1.5; CaCl 2 2.5; KCl 4.7 and glucose 11, cleaned from serosal fat, mucosal layer and tenia coli leaving the smooth muscle bands. Part of this muscle was weighed, frozen and stored in liquid nitrogen and then used to prepare membranes for radioligand binding experiments. The remainder part of the tissue was used for functional studies by dissecting strips (3 mm wide by 10-15 mm long; 5-8 from each segment) of muscular tissue in the direction of circular muscular fibers. All strips for functional studies were stored overnight at 4 1C in oxygenated (95% O 2 and 5% CO 2 ) Krebs solution. All salts used were of analytical grade and purchased from Merck (Darmstadt, Germany). All other materials were from Sigma-Aldrich (Milano, Italy).
Chemicals
Membranes preparation
Crude membranes were prepared as described in Burcher et al. (1986) and Warner et al. (1999) with minor modifications. All of the following procedures were performed at 4 1C. Tissues were thawed on ice and then placed in 15 volumes of 50 mM Tris containing 120 mM NaCl and 5 mM KCl (pH 7.4). It was first minced by using fine scissors and then homogenized by using a homogenizer (Ultra-Turrax T25, IKA Labortechnik) set at 20,500 loads min À 1 . The homogenate was centrifuged at 48,000 g for 20 min and the pellet was re-homogenized and re-suspended in 50 mM Tris HCl (pH 7.4) containing 10 mM EDTA and 300 mM KCl for 1 h. After centrifugation as before, the membranes were washed twice in 50 mM Tris HCl. Before the last centrifugation the protein content was determined according to Bradford (1976) . The membranes were finally re-suspended in binding buffer.
Radioligand binding studies
The binding buffer was 50 mM Tris HCl (pH 7.4) containing 0.02% bovine serum albumin (BSA), 3 mM MnCl 2 , 100 mg/ml bacitracin, 10 mg/ml chymostatin, 5 mg/ml leupeptin, and 2.5 mg/ ml thiorphan. Non-specific binding was defined as the amount of radiolabelled ligand bound in the presence of unlabeled NKA (1 mM). Preliminary experiments were performed to verify the protein concentration to be used (about 70-100 mg/ml, final concentration) and the time to reach the radioligand binding steady state (60 min 
Functional studies
The strips (15-20 h after excision) were placed in 5-ml organ baths filled with oxygenated Krebs solution at 37 1C and connected to isometric force transducers (Ugo Basile, Varese, Italy) under an initial tension of 20 mN. Mechanical activity was amplified and digitally recorded by an Octal Bridge Amplifier connected to PowerLab/8sp hardware system and analyzed using the Chart 4.2 software (AD Instruments, Australia).
The activity of ibodutant at the human tachykinin NK 2 receptors was evaluated against the selective NK 2 receptor agonist [bAla 8 ]NKA(4-10) (Maggi et al. 1993) in the presence of atropine
(1 mM), indomethacin (3 mM) and the selective tachykinin NK 1 receptor antagonist SR140333 (0.1 mM).
After 60 min stabilization period two reproducible responses to 80 mM KCl were established at 45 min intervals to assess tissue viability. After a further 45 min equilibration period, during which the medium was renewed every 15 min, nifedipine (0.3 mM) was added to the Krebs solution and there was left in all subsequent experimental phases to eliminate spontaneous activity (Maggi et al. 1989; Zagorodnyuk et al. 1994) . After 30 min of incubation in the presence of nifedipine the preparations were challenged with 1 mM [bAla 8 ]NKA(4-10) to evaluate the contractile response of each preparation.
After a further 90 min equilibration period, concentrationresponse curves to the tachykinin NK 2 receptor selective agonist [bAla 8 ]NKA(4-10), were cumulatively constructed. In each experiment one strip was pretreated with the vehicle (DMSO; 1-3 ml/ml) and used to perform the control curve to [bAla 8 ]NKA(4-10), while the other strips, obtained from the same specimen, were pretreated with ibodutant (3, 10, 30 and 100 nM) added to the organ bath 60 min before the concentration-response curve to [bAla 8 ]NKA(4-10). In each preparation only one cumulative concentration-response curve to [bAla 8 ]NKA(4-10) was carried out and only one concentration of the antagonist was tested.
In a separate series of experiments the reversibility of tachykinin NK 2 receptors blockade produced by ibodutant was evaluated in the human colon preparations using the technique as described by Patacchini et al. (2000) and by Meini et al. (2009) . These experiments were also performed in the presence of atropine (1 mM), indomethacin (3 mM), SR140333 (0.1 mM) and nifedipine (0.3 mM). After a stabilization period of 60 min, preparations were exposed twice, every 30 min, at a submaximal concentration (171 nM) of [bAla 8 ]NKA(4-10), calculated from control concentration response curve of the agonist, as the one producing 90% of its maximal contractile effect. After further 30 min, ibodutant (10, 30, 100 and 300 nM) or the vehicle (DMSO, 1-3 ml/ml) were added to the bath solution and incubated for 60 min before the next challenge with the agonist (Time 0). After the agonist had produced its maximum contractile effect, the preparations were subjected to a washing protocol of the agonist and the antagonist consisting of three washing periods lasting 10 s each every 10 min during which the volume of the organ bath was renewed five times for each washing period (15 renewals in all). Thereafter the administration of the agonist was repeated every 30 min in antagonist-free solution to measure the reversibility of antagonist action for 180 min.
Data evaluation and statistical analysis
All data in the text or figures are expressed as mean 7standard error of the mean (S.E.M.) or 95% confidence limits (95% c.l.).
Data from radioligand binding experiments were fitted by nonlinear regression using GraphPad Software Prism 4.02 to determine the equilibrium dissociation constant (K d ) from homologous competition experiments performed with NKA, and the ligand concentration inhibiting the radioligand binding of the 50% (IC 50 ) from heterologous competition experiments (ibodutant, saredutant and nepadutant (Cheng and Prusoff, 1973) in each experimental section (using tissue from the same donor). For graphical presentation data obtained at each concentration of competing ligand, were normalized as percentage of specific binding as follows: [(bound-nonspecific)/specific] Â 100.
Functional data were fitted by sigmoidal nonlinear regression (Prism 4.02, GraphPad Software) to determine the agonist concentration producing the 50% (EC 50 ) of the maximal response from the concentration-response curves. Differences in the maximum contractile effects between controls and ibodutantpretreated preparations were evaluated by one-way Analysis of Variance (ANOVA) and the Dunnett Multiple Comparison Test.
The antagonist potency of ibodutant was expressed in terms of pK B estimated as the mean of the individual values obtained with the Gaddum equation: pK B ¼log(CR À 1) Àlog [B] were CR is the concentration-ratio calculated from equieffective concentrations of agonist (EC 50 ) obtained in the presence and in the absence of antagonist and B is the used antagonist concentration (Kenakin, 2006) .
Competitive antagonism was checked by the Schild regression analysis by plotting the estimates of log(CR À 1) against log[B] to determine the slopes of linear regression: a plot with linear regression line and slope not significantly different from unity was considered as proof of competitive antagonism (Arunlakshana and Schild, 1959) .
In reversibility experiments of tachykinin NK 2 receptor blockade produced by antagonists performed in the human colon preparation responses obtained in each strip at different time were percentaged towards the basal response obtained in each preparation (before antagonist treatment), and compared to those obtained in control time-matched preparations. Data obtained were analyzed by two-way analysis of variance (ANOVA) for repeated measures followed by the Bonferroni post-test. ]NKA(4-10)
Results
Radioligand binding inhibition experiments
In the presence of atropine (1 mM), indomethacin (3 mM), SR140333 (0.1 mM) and nifedipine (0.3 mM) the selective NK 2 receptor agonist [bAla 8 ]NKA(4-10) produced slowly developing, concentration-dependent, tonic contractions of the human isolated circular colon: the E max was 34.672.6 mN (n ¼13). The EC 50 value calculated from control (vehicle-treated) concentrationresponse curves to [bAla 8 ]NKA(4-10) was 12.4 nM (95% c.l.
11.1 À 13.9; n ¼13). Ibodutant (3, 10, 30 and 100 nM) was devoid of any effect on the resting tension of the preparation whereas it concentrationdependently and with high potency antagonized [bAla 8 ]NKA (4-10) -induced contractile responses producing a parallel rightward shifts ( Fig. 2A) ]NKA(4-10) averaged 15.4 nM (95% c.l. 12.6-18.9) and 10.3 nM (95% c.l. 9.3-11.5) (n¼5 and n¼8, respectively, n.s.) in strips from male and female, respectively.
With regard to ibodutant the analysis of its antagonist potency toward [bAla 8 ]NKA(4-10) yielded an apparent pK B value of 9.0 70.1 and 9.170.05 (n ¼18 and n ¼31, respectively, n.s.) in colonic strips from male and female patients, respectively.
Reversibility of functional tachykinin NK 2 receptor blockade
Reversibility of functional tachykinin NK 2 receptor blockade by ibodutant was evaluated by measuring the capability of the human colon muscle to recover the control contractile response produced by a single submaximal concentration (171 nM) of [bAla 8 ]NKA(4-10) which induced about 90% of its maximum contractile effect and amounted to 29.7 73.2 mN (n ¼15). After the incubation period of 60 min, ibodutant (10, 30, 100 and 300 nM) produced a significant concentration-dependent inhibition of the contractile effect produced by [bAla 8 ]NKA(4-10). At this time (Time 0) the inhibitory effect induced by ibodutant was 2379, 55712, 7376 and 8478% at 10, 30, 100 and 300 nM, respectively (Fig. 3) . The inhibition remained constant for all concentrations tested with no recovery of the subsequent responses to the agonist obtained in drug-free medium for 180 min.
Discussion
In this study the pharmacological characterization of the tachykinin NK 2 receptor antagonist ibodutant (MEN15596) is presented in the circular smooth muscle of human colon, and the high affinity and antagonist potency, besides the long duration of action of this antagonist, proved also in this tissue.
The determination of ibodutant affinity through radioligand binding experiments indicate that this antagonist recognizes the NKA binding sites present in the human colon with a significant high affinity (pK i 9.9). In the same experiments the affinity of the others tachykinin NK 2 receptor antagonists, nepadutant and saredutant, was evaluated as well. Present results indicate that overall the rank order of affinity values for the three antagonists, ]NKA(4-10) in the human colon smooth muscle or the inositol phosphates accumulation induced by NKA in CHO/hNK 2 R.
a Meini et al., 2009 . b Renzetti et al., 1999 . c Patacchini et al., 2000 . i.e. ibodutant (pK i 9.9) 4saredutant (pK i 9.2) 4nepadutant (pK i 8.4), well matches with that previously obtained at the human recombinant tachykinin NK 2 receptor (ibodutant pK i 10.8, saredutant pK i 9.8, nepadutant pK i 8.5; Meini et al., 2009; Renzetti et al., 1999) . The affinity of saredutant and nepadutant was previously shown in the human colon also by Warner et al. (1999) and the calculated pK i values are in a similar range (saredutant 9.5 and nepadutant 9.1).
The antagonist potency of ibodutant estimated at the NK 2 receptors of the human colon in the present study was similar (pK B 9.170.05) to that found in human urinary bladder (pK B ¼9.2), guinea-pig colon (pK B ¼ 9.3) and minipig urinary bladder (pK B ¼8.8) NK 2 receptor smooth muscle preparations (Cialdai et al., 2006) , but also in the inositol phosphates accumulation induced by NKA in CHO cells expressing the human NK 2 receptor (pK B 10.3-10.6) (Meini et al., 2009) .
The Schild analysis yielding to a slope (1.02) not significantly different from unity clearly indicates the competitive antagonist behavior of ibodutant in antagonizing the NK 2 receptor-mediated motor responses produced by the application of the selective NK 2 receptor agonist [bAla 8 ]NKA(4-10). In a previous study Burcher et al. (2008) reported a significantly higher B max value for NK 2 receptor in male as compared to female human colon, although no differences in NK 2 receptor mRNA were observed as well as no difference in potency and maximal responses to NKA or [Lys 5 , MeLeu 9 , Nle 10 ]-NKA(4-10) were detected. Likewise, we failed to detect any gender differences in the contractile response to [bAla 8 ]NKA(4-10) nor in the antagonist potency of ibodutant.
Overall the results of Burcher et al. (2008) and the present results offer little ground to speculate for a gender-related differential role of NK 2 receptors in the genesis of symptoms of IBS. We have previously shown (Cipriani et al., 2011 ) that ibodutant prevents internalization of NK 2 receptors induced by [bAla 8 ]NKA(4-10) in human colon. The receptor internalization is unlikely to be relevant for present findings because: (a) the techniques used to highlight receptor internalization requires a prolonged exposition to the agonist at very low temperature followed by a rapid heating, far different in terms of kinetics from the present experimental conditions; (b) the protocol used in this study enables reproducible responses to NK 2 receptor agonists to be performed at relatively short (30 min) time intervals thus indicating that receptors internalization, if any, is negligible.
The kinetic profile of ibodutant was previously observed at molecular level and its fast associating and slow dissociating properties in the interaction with the human tachykinin NK 2 receptor assessed (Meini et al., 2009 ). In the current investigation, the kinetic of ibodutant interaction at the NK 2 receptor was evaluated by using a functional experimental approach. Present data indicate that ibodutant persistently binds to the human tachykinin NK 2 receptor expressed in the human colon smooth muscle, as the inhibition of the motor response induced by [bAla 8 ]NKA(4-10) does not recover during the 3h observation period in drug-free medium. These data obtained with ibodutant resemble those previously observed with the tachykinin NK 2 receptor antagonist saredutant in the same experimental model (Patacchini et al., 2000) . On the other hand, although the functional receptor blockade exerted by ibodutant (present study) or by saredutant (Patacchini et al., 2000) in the present assay appear to be similar, analogs experiments performed in a cell system (Meini et al., 2009) indicated that despite of their slow dissociation, both antagonists exerted a reversible functional blockade. The different behavior obtained in the cell system and in the smooth muscle tissue can be ascribed to the different experimental parameters used, such as the concentrations of used agonist and antagonist and the kinetics of the measured response.
On the other hand, despite the very slow dissociation property of both ibodutant and saredutant they are endowed of a different antagonist behavior. In particular although ibodutant slowly reverts from the receptor compartment it exerts a surmountable competitive antagonism type (present study, Meini et al., 2009) , whereas saredutant was reported to display an insurmountable antagonism both in contractility smooth muscle (Patacchini et al., 2000) and cell system assays (Meini et al., 2009 ). NKA, via NK 2 receptors, has been already documented to be a major mediator of the non-adrenergic non-cholinergic (NANC) excitatory imput to the circular muscle of human ileum (Maggi et al., 1992) and colon (Cao et al., 2000; Aulí et al., 2008 ). It appears therefore that the role of NKA as excitatory NANC enteric neurotransmitter, as widely documented to exist in various mammalian species (Holzer and Holzer-Petsche, 1997a,b) , is largely maintained in humans and there is abundant evidence associating tachykinins with altered gastrointestinal motility, secretion and visceral sensitivity (Lecci et al., 2004 for review) thus making the field of tachykinins antagonists an appealing target for the development of a new pharmacological treatment of IBS.
The present findings, which document the potent and long lasting NK 2 receptor antagonist activity of ibodutant in human colon, support the concept that this molecule is suitable candidate for therapeutic strategies aiming at a control of exaggerated intestinal motility. Ibodutant is currently undergoing Phase II clinical trial in IBS patient with predominant diarrhea. 
